## **BMC Neurology**

# Study Protocol: ASCRIBED: The impact of Acute SystematiC inflammation upon cerebRospinal fluid and blood BiomarkErs of brain inflammation and injury in Dementia: a study in acute hip fracture patients --Manuscript Draft--

Manuscript Number:	NURL-D-19-00496R2				
Full Title:	Study Protocol: ASCRIBED: The impact of Acute SystematiC inflammation upon cerebRospinal fluId and blood BiomarkErs of brain inflammation and injury in Dementia: a study in acute hip fracture patients				
Article Type:	Study protocol				
Section/Category:	3.Dementias				
Funding Information:	Alzheimer's Research UK (ARUK-PG2016B-12)	Professor Chris Fox			
Abstract:       Background: Hip fracture represents a substantial acute inflammatory trauma, may constitute a significant insult to the degenerating brain. Research sugges injury of this kind can affect memory and thinking in the future but it is unclear and how, inflammatory trauma injures the brain. The impact of Acute Systema inflammation upon cerebRospinal fluld and blood BiomarkErs of brain inflamm and injury in Dementia: a study in acute hip fracture patients (ASCRIBED) exp relationship, to understand the effect of inflammation on the progression of de Methods: This protocol describes a multi-centre sample collection observation The study utilises the unique opportunity provided by hip fracture operations undertaken via spinal anaesthesia to collect cerebrospinal fluid (CSF) and bloo investigate the impact of acute brain inflammation caused by hip fracture on th exacerbation of dementia. We will recruit 200 hip fracture patients with a diagr evidence of dementia; and 200 hip fracture patients with a diagr evidence of dementia; CSF and blood samples from a cohort of dementia and to expreienced a systemic inflammatory response due to injury. This provide a comparison between patients with and without dementia who are su systemic inflammatory response; with stable patients living with dementia. Dis We will test the hypothesis that hip fracture patients living with dementia. Dis We will test the hypothesis that systemic inflammatory events can exacerbate underlying dementia, and inform the search for new treatments targeting inflam to editors the thout dementia. Reserved by biomarkers in CSF and blood. The will address the hypothesis that systemic inflammatory events can exacerbate underlying dementia and inform the search for new treatments targeting inflam to dementia. Trial Registration: ISRCTN43803769. Registered 11 May 2017. https://doi.org/10.1186/ISRCTN43803769. Keywords: dementia, hip fracture, buto dementia in dementia. An inform the search for new treatments t					
Corresponding Author:	Chris Fox University of East Anglia Norwich, Norfolk UNITED KINGDOM				
Corresponding Author E-Mail:	Author E-Mail: Chris.Fox@uea.ac.uk				
Corresponding Author Secondary Information:					
Corresponding Author's Institution:	University of East Anglia				
Corresponding Author's Secondary Institution:					
First Author:	Nick Leavey, MSc				
First Author Secondary Information:					
Order of Authors:	Nick Leavey, MSc				

	Simon Hammond
	Lee Shepstone
	Jane Cross
	Henrik Zetterberg
	Colm Cunningham
	Alasdair MacLullich
	Leiv Otto
	Anne Marie Minihane
	Clive Ballard
	Anne-Brita Knapskog
	Roanna Hall
	Gregory Howard
	Matt Hammond
	Chris Fox
Order of Authors Secondary Information:	
Response to Reviewers:	Tables and figure reloaded

## Click here to view linked References

ASCRIBED Protocol Paper

-----

1	1	Study Protocol: ASCRIBED: The impact of Acute SystematiC inflammation upon cerebRospinal
2 3	2	fluId and blood BiomarkErs of brain inflammation and injury in Dementia: a study in acute hip
4 5 6	3	fracture patients
7 8	4	
9 10 11	5	Authors: Nick Leavey (Norwich Clinical Trial Unit, Norwich Medical School, Faculty of Medicine and
11 12 13	6	Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ.
14 15	7	Nickleavey@hotmail.com), Simon P Hammond (School of Education and Lifelong Learning, Faculty of
16 17 18	8	Social Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ.
19 20	9	S.Hammond@uea.ac.uk). Lee Shepstone (Norwich Medical School, Faculty of Medicine and Health
21 22	10	Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ.
23 24 25	11	L.Shepstone@uea.ac.uk), Jane Cross (School of Health Sciences, Faculty of Medicine and Health
26 27	12	Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ. J.Cross@uea.ac.uk),
28 29 30	13	Henrik Zetterberg (Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the
30 31 32	14	University of Gothenburg, S-431 80 Mölndal, Sweden; Clinical Neurochemistry Laboratory,
33 34	15	Sahlgrenska University Hospital, S-431 80 Mölndal, Sweden; Department of Neurodegenerative
35 36 37	16	Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom; UK
38 39	17	Dementia Research Institute at UCL, Cruciform Building, Gower Street, London WC1E 6BT, United
40 41	18	Kingdom. <a href="https://www.settor.com">https://www.settor.com</a> , Colm Cunningham (School of Biochemistry and
42 43 44	19	Immunology, Trinity Biomedical Sciences Institute & Trinity College Institute of Neuroscience, Trinity
45 46	20	College Dublin. <u>Cunninco@tcd.ie</u> ), Alasdair MacLullich (Edinburgh Delirium Rese arch Group,
47 48 40	21	Geriatric Medicine, University of Edinburgh, Room S1642, Royal Infirmary Edinburgh, EH16 4SA.
49 50 51	22	A.Maclullich@ed.ac.uk), Leiv Otto Watne (Oslo Delirium Research Group, Department of Geriatric
52 53	23	Medicine, Oslo University Hospital, PO box 4950 Nydalen, N-0424 Oslo, Norway.
54 55 56	24	I.o.watne@gmail.com). Anne Marie Minihane (Norwich Medical School, BCRE, James Watson Road,
57 58	25	University of East Anglia, Norwich, NR4 7UQ. <u>A.Minihane@uea.ac.uk</u> ), Clive Ballard (Wolfson Centre
59 60	26	for Age Related Diseases, King's College London Guy's Campus, Hodgkin Building, London, SE1 1UL.
61 62 63 64		1

\_\_\_\_\_

Clive.Ballard@kcl.ac.uk). Anne-Brita Knapskog (Department of Geriatric Medicine, Oslo University Hospital, Ullevaal, Postbox 4956, Nydalen, Oslo, Norway. anne-brita@knapskog.net). Roanna Hall (Department of Geriatric Medicine, University of Edinburgh Room S1642, New Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, Midlothian, United Kingdom. EH16 4SA. roanna.hall@nhslothian.scot.nhs.uk). Gregory Howard (Norwich Clinical Trial Unit, Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ. Gregory.Howard@uea.ac.uk), Matt Hammond (Norwich Clinical Trial Unit, Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ. M.Hammond@uea.ac.uk), Chris Fox\* (Department of Psychological Sciences, Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ. Chris.Fox@uea.ac.uk), \*Corresponding author: Chris Fox Abstract Background: Hip fracture represents a substantial acute inflammatory trauma, which may constitute a significant insult to the degenerating brain. Research suggests that an injury of this kind can affect memory and thinking in the future but it is unclear whether, and how, inflammatory trauma injures the brain. The impact of Acute SystematiC inflammation upon cerebRospinal fluld and blood BiomarkErs of brain inflammation and injury in Dementia: a study in acute hip fracture patients (ASCRIBED) explores this relationship, to understand the effect of inflammation on the progression of dementia. Methods: This protocol describes a multi-centre sample collection observational study. The study utilises the unique opportunity provided by hip fracture operations undertaken via spinal

anaesthesia to collect cerebrospinal fluid (CSF) and blood, to investigate the impact of acute brain inflammation caused by hip fracture on the exacerbation of dementia. We will recruit 200 hip fracture patients with a diagnosis or evidence of dementia; and 200 hip fracture patients without dementia. We will also recruit 'Suitable informants', individuals in regular contact with the patient, to provide further proxy evidence of a patient's potential cognitive decline. We will compare these 400 samples with existing CSF and blood samples from a cohort of dementia patients who had not experienced a systemic inflammatory response due to injury. This will provide a comparison between patients with and without dementia who are suffering a systemic inflammatory response; with stable patients living with dementia.

Discussion: We will test the hypothesis that hip fracture patients living with dementia show elevated markers of brain inflammation, as well as neuronal injury and Alzheimer-related plaque pathology, in comparison to (1) stable patients living with dementia and (2) hip fracture patients without dementia, as measured by biomarkers in CSF and blood. The findings will address the hypothesis that systemic inflammatory events can exacerbate underlying dementia and inform the search for new treatments targeting inflammation in dementia.

## **Trial Registration:** ISRCTN43803769. Registered 11 May 2017.

## 67 <u>https://doi.org/10.1186/ISRCTN43803769</u>

Keywords: dementia, hip fracture, inflammation, cerebrospinal fluid.

## 69 Background

Inflammation is a beneficial physiological response to tissue damage or infection. However, when
inflammation is extensive or not fully resolved, this can damage healthy tissues and disrupt normal
cellular function. Hip fracture represents a substantial systemic inflammatory trauma, common in
older people, which may constitute a significant insult to the degenerating brain and therefore
contribute to the progression or even the onset of dementia. Hip fracture in older people has

therefore been linked with poor cognitive outcomes, including delirium in the short-term, increased
dependency and cognitive decline, especially in patients with dementia [1, 2, 3].

The association and pathological role of inflammation in dementia has been extensively described
[4]. Studies have shown that microglial cells (the brain's main macrophage population) are activated
in the vicinity of amyloid plaques in dementia [5]. More recent studies suggest that altered
macrophage function may contribute to dementia [6]. Animal studies have shown that microglial
activation is a consistent feature in dementia and there is evidence that inflammation contributes to
the disease process [7, 8] but the physiological and molecular basis for this remains unclear.

Current evidence from human epidemiological studies, human data from blood, cerebrospinal fluid and imaging, and animal models, have established that alongside chronic localised inflammation resulting from and contributing to neurodegenerative diseases such as dementia, there is also neurodegeneration induced by acute inflammatory processes [9] and changes in amyloid processing [10]. Understanding this alternative route to neurodegeneration is becoming increasingly important as the population ages. This is because acute systemic inflammatory episodes, such as infection and inflammatory trauma, are common in older people with some evidence of this having both acute [11] and lasting [12] impacts on cognitive function. Therefore, it is plausible that such episodes are an important cause of decline in people living with dementia, which is clinically almost completely unaddressed.

With rapid advances in identifying and measuring/testing cerebrospinal fluid (CSF) and blood
biomarkers of brain inflammation, brain injury and Alzheimer-associated amyloid β (Aβ) plaque
pathology, there is the opportunity to study this in humans.

96 Previous studies in older people with acute systemic inflammation have been limited by small
97 sample sizes, the lack of adequate control groups and, in particular, have not assessed the impact of
98 inflammation on recently emerging biomarkers of new brain injury [13].

One of the other difficulties encountered by research in this area is that hip fracture is an emergency and studies cannot directly collect pre-fracture data. However, well-validated methods for the assessment of pre-fracture cognitive ability are available. The Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE [15] is one example widely-used clinically and for research purposes. In the United Kingdom (UK) a significant proportion of hip fracture patients undergo surgery within spinal anaesthesia [16]. This routine clinical procedure involves inserting a needle into the patient's spinal space (subarachnoid space) and injecting anaesthetic into the CSF. In this way, CSF can be collected just before the initiation of anaesthesia, using the same needle that will be used to administer the anaesthetic agent. This means that older patients undergoing emergency hip fracture repair surgery are a suitable group in which to measure systemic inflammation, brain inflammation and CSF markers of brain injury.

The impact of Acute SystematiC inflammation upon cerebRospinal fluid and blood BiomarkErs of brain inflammation and injury in Dementia: a study in acute hip fracture patients (ASCRIBED) will use the opportunity provided by hip fracture operations undertaken via spinal anaesthesia to investigate the impact of acute systematic inflammation upon CSF and blood biomarkers of brain inflammation and neuronal injury and on the exacerbation of dementia. We will collect samples from patients with and without dementia who are suffering a systematic inflammatory response (the ASCRIBED cohort). We will compare ASCRIBED's 'unstable' groups (termed as to refer to the inflammatory response) with an existing cohort of patients living with dementia who have not experienced a systemic inflammatory response from an injury (henceforth known as the 'Oslo' cohort). The Oslo cohort will therefore provide 'stable' comparators. The study will shed light on the ability of acute inflammatory trauma to produce new brain injury in a vulnerable older population. The findings will then inform the search for new treatments targeting inflammation in dementia.

## 123 Methods

## 124 Aims and objectives

In order to have specific measures informing on the severity of prevalent systemic inflammation at the time of lumbar puncture (*i.e.*, the time of CSF collection), matched to those inflammatory mediators occurring in the CSF, we will quantify inflammatory mediators (including but not limited to IL-1 $\beta$ , TNF- $\alpha$ , IL-6) in both peripheral blood and in CSF. In order to assess brain injury we will measure CSF markers of brain injury (including but not limited to total and phosphorylated tau [T-tau and P-tau, respectively], neurofilament light [NfL] and neurogranin). Brain injury markers will also be measured in blood.  $A\beta 42/40$  ratio in CSF and plasma, measured using immunoassays (Meso Scale Discovery and Simoa methods, respectively), will be used as a biomarker of cerebral AB pathology. We will also collect an additional 2.5ml of whole blood from patients. Several studies have recently been published using PAXgene blood collection tubes for later transcriptomic analysis. Our intention is to place ourselves in the position to examine blood signatures that associate with, and may be predictive of, particular CSF and clinical outcomes in our patients for later analysis. Banking these samples will enable further in-depth analysis and is in accordance with the trial ethical approval and consent process.

## 140 Primary Objective

To determine whether hip fracture patients living with dementia show elevated markers of brain
inflammation in comparison to (1) stable patients living with dementia and (2) hip fracture patients
without dementia, as measured by biomarkers in CSF. CSF inflammation will be measured by TNF-α,
IL-1RA, IL-1β, IL-6 and brain injury and biomarkers will be measured by NfL, neurogranin, T-tau,
synaptotagmin and SNAP-25.

### 147 Secondary Objectives

To determine whether the magnitude of the brain inflammatory response predicts the quantity of specific brain injury markers measured in the CSF. Magnitude of the brain injury will be assessed via brain injury markers T-tau, P-tau, NfL, neurogranin, synaptotagmin and SNAP-25 in CSF. We will also examine if patients who are Aβ-positive at baseline are more or less likely to have dementia or develop dementia at follow-up. We will also look for interactions of Aβ positivity with the other biomarkers in regards to clinical outcome.

154 Design

This observational study will recruit patients with proximal hip fractures who undergo surgery via spinal anaesthesia. The majority of patients admitted with a hip fracture are cognitively vulnerable. This may be a pre-fracture state or an acute reaction to the hip fracture. Clinically, patients arriving in acute settings do not always arrive with a confirmed dementia diagnosis. However, in the UK, it is routine clinical practice to cognitively screen hip fracture patients over the age of 60 years. In England, the Abbreviated Mental Test (AMT) is commonly used [17]. In Scotland, the 4AT is used as best standard practice [18]. Because evidence highlights that the mapping of a patient's score on the 4AT on to the AMTS is possible [19, 20], we will use routinely available clinical data to pre-operatively assign recruited patients to one of two groups, either 'confused' or 'non-confused'. In this way, we will employ the term confusion to reflect the real-world complexity of the acute hospital environment and initially assign patients accordingly, based on these existing cognitive clinical screening practices (see figure 1). Specifically, Group 1 patients will have a pre-op AMT score of  $\leq$  8 (England), or a 4AT score of > 1 (Scotland); and Group 2 patients will have a pre-op AMT score of > 9 (England) or 4AT score of 0 (Scotland). 

Whilst these are indicative of the possibility that the patient may have some form of
dementia/cognitive impairment, it is often not possible to obtain confirmative evidence until at least
171 1-month post-op. Using the AMT or 4AT scores allows us to allocate patients to a group at the

recruitment stage. However, we will also take into account any subsequent evidence of dementia in the analysis, by gaining permission/consent to access a patient's notes and/or where possible, a consented suitable informant (someone who has contact with the patient at least once a month face-to-face or via telephone) via the Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE). This will inform what final group cohort the patient is then allocated to. In the absence of a formal documented diagnosis of dementia and in accordance with previous research [21, 22], patients with an associated suitable informant IQCODE score of 3.31 and above will be assessed as having sufficient evidence of dementia to be allocated to the corresponding group cohort.

**INSERT FIGURE 1: STUDY DIAGRAM AND GROUP ALLOCATION OF PATIENTS** 

81 Setting

The study setting is acute trauma wards in hospitals across England and Scotland to which individuals suffering Neck of Femur (NoF) fractures are admitted. In all instances, the investigator(s) will be able to demonstrate a potential for recruiting the required number of suitable participants within the agreed recruitment period (i.e. the investigator(s) regularly treat(s) the target population). For these reasons, the study management team will target NHS Hospitals with large annual admission rates of NOF fractures with sufficiently high percentages of operations being undertaken via spinal anaesthesia. This information was readily available through the National Hip Fracture Database (NHFD) for all NHS Trusts in England [17]. In Scotland, we targeted large centres known to the study group and with existing expertise in collecting CSF for research purposes.

191 Participants

We will be collecting samples and data from two groups of patient participants (n=200 in each group). Due to the cognitively vulnerable nature of the patient population and feasibility learning in relation to dementia diagnosis rates of our target population [23], we will seek proxy information about pre-fracture cognition to inform grouping allocation for analysis. Consequently, we will also seek written consent from "suitable informants" as defined by the inclusion criteria below, to

1	197	complete the Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE). The
2	198	recruitment of a suitable informant for each patient is desirable, but not essential. The eligibility
4 5 6	199	criteria for patient participants and suitable informant participants are as follows:
7 8 9	200	Patient inclusion criteria:
10 11 12	201	Group 1: 'Confused' hip fracture patients
13 14 15	202	Inclusion Criteria:
16 17 18		1) Patient must have had a confirmed proximal hip fracture requiring an operation and be aged
19 20	204	60 or older at the time of operation;
21 22 23		2) Patient has a pre-operative Abbreviated Mental Test Score (AMTS) of 8 or below; or 4AT
23 24 25	206	score of 1 or above;
26 27	207	3) Patient must be undergoing spinal anaesthesia.
28 29 30	208	Exclusion criteria:
31 32 33		1) Decision taken not to have hip surgery;
34 35 36		2) Patient has head trauma with bleeding as indicated by a CT scan;
37 38	211	3) Patient has confirmed diagnosis of Parkinson's disease;
39 40		4) Patient not expected to survive beyond 4 weeks;
41 42 43	213	5) Patient's fall and subsequent hip fracture caused by acute Stroke, indicated by CT and/or
44 45		MRI scan and/or clinical examination;
46 47 48	215	6) Patient already enrolled in a Clinical Trial of an Investigational Medicinal Product (CTIMP).
49 50 51	216	Group 2: 'Non-confused' hip fracture patients
52 53	217	Inclusion Criteria:
54 55 56	218	1) Patient must have had a confirmed proximal hip fracture requiring an operation and be aged
57 58 59	219	60 or older at the time of operation;
60 61	220	2) Patient has a pre-operative AMTS of 9 or above; or 4AT score of 0;
62 63		9
64 65		

1	221	3) Patient must be undergoing spinal anaesthesia.				
2 3 4	222	Exclusi	on criteria:			
5 6 7	223	1)	Decision taken not to have hip surgery;			
8 9	224	2)	Patient has head trauma with bleeding as indicated by a CT scan.			
10 11 12	225	3)	Patient has confirmed diagnosis of Parkinson's disease;			
13 14	226	4)	Patient not expected to survive beyond 4 weeks;			
15 16 17	227	5)	Patient's fall and subsequent hip fracture caused by acute Stroke, indicated by CT and/or			
18 19	228		MRI scan and/or clinical examination;			
20 21 22	229	6)	Patient already enrolled in a Clinical Trial of an Investigational Medicinal Product (CTIMP).			
23 24	230	Suitabl	le informants			
25 26 27	231	Inclusio	on Criteria:			
28 29 30	232	1)	Individual has a minimum of once a month face-to-face or telephone contact with the			
31 32	233		patient;			
33 34 35	234	2)	Individual is able and consents to complete the IQCODE.			
36 37 38	235	Exclusi	on Criteria:			
39 40 41	236	1)	Individual under 16 years of age.			
42 43 44	237					
45 46 47	238	Recrui	itment and Consent Procedures			
48 49	239	A three	e-phase recruitment process has been guided by conversations with clinical and academic			
50 51 52	240	collaborators and previous experience recruiting from this patient group [23].				
53 54 55	241	1)	Research Nurses will collaborate with relevant clinical staff (including but not exclusively t	ne		
56 57	242	study v	vard Trauma Co-ordinators and key Emergency Department colleagues) to identify all new h	nip		
58 59 60 61 62	243	fracture	e admissions and screen for pre-recruitment eligibility;	10		
63				-0		

2) Each patient (and where possible their potential suitable informant) will be approached by a Research Nurse who will provide information about the study as soon as clinically appropriate. During this initial approach, the Research Nurse will also assess the mental capacity of the patient; 3) The Research Nurse will approach the patient (where possible) and the identified suitable informant to obtain full written informed consent. In cases where written consent is not possible, ethical approval allows for witnessed verbal consent.

In English trial sites, in line with Principle 1 of the Mental Capacity Act 2005 [24], a potential patient participant will be assumed to have capacity until it is established otherwise. When this is the case and all practical steps to help them to engage in the decision making process have been tried (Principle 2 of Mental Capacity Act 2005), the site trial team will seek a personal consultee. This person will be someone who is engaged in care for the participant (not professionally or for payment) or is interested in his/her welfare and is prepared to be consulted. This may be a family member, carer or close friend, or attorney acting under Lasting Power of Attorney. This person can also act as a suitable informant if they fulfil the inclusion criteria.

If a potential personal consultee is not available or declines to take part, alternatively a nominated consultee will be sought. This will be a person independent of the research study and who is willing to be consulted about the participation of a person who lacks capacity where reasonable steps have been taken to identify a personal consultee. This may be someone who knows the patient in a professional capacity e.g. social worker, ward staff member, paid carer or GP, provided they have no connection to the research study.

In Scottish sites, in line with the Adults with Incapacity Act 2000 [25], where a potential patient participant is assessed not to have capacity, a welfare guardian, welfare attorney or nearest relative will be sought and asked to consent in relation to participation in research (this person will be henceforth known as a legal representative). This procedure will be undertaken once an assessment of capacity has been made in relation to the specific decision regarding the research participation,

any barriers to participating in the consent process have been removed and the local research
worker feels the individual cannot retain information long enough to use it in order to arrive at a
decision.

Legal representatives may be involved in conversations regarding the consenting process. However, they will be asked to differentiate between expressions of their own views and reporting the known values and/or views of the potential patient participant. If the potential participant is unable to consent for himself or herself, then consent will be sought on their behalf from a suitable legal representative.

In cases where gaining full written consent is not possible research workers may take witnessed
verbal consent (patients or legal representatives) or agreement (personal consultees). For patients
this may be needed due to an inability to write because of injury. With personal consultees or legal
representatives this may be due to distance therefore study information may be conveyed over the
phone with relevant forms sent via email if appropriate. Where witnessed verbal
agreement/consent is taken, full written agreement/consent will be sought where practically

283 possible. A record of all witnessed verbal consent will be added to the patient's notes.

In both England and Scotland, if during a follow-up assessment the patient is assessed by a local research worker to have regained capacity (a possibility in the case of some cognitive impairments such as delirium); he/she will be approached about continuing to participate in the study and asked to give informed consent. Should they choose to withdraw from the study at this point, the study team reserve the right to retain any data and samples collected up until the point of the patient's withdrawal. This will be clearly stated in the patient and Consultee (English sites)/Legal

290 Representative (Scottish Sites) Information Sheets.

This three-phase process will be closely monitored to identify trends that might be leading to over or
under recruitment from specific groups. For example, if sites are consenting purely via personal

293 consultees (England) or legal representatives (Scotland), monitoring will enable corrective actions
294 and provide information to mitigate these recruitment trends.

> Recruiting patients with fluctuating and/or reduced capacity in England and Scotland The aims of this study are incompatible with only enrolling patients with minimal or mild confusion. It is important to ensure findings are broadly applicable to those patients with a pre-existing diagnosis or evidence of dementia. Participants who lack capacity to give informed consent must therefore be included. In this situation, the patient's agreement to participate will still be obtained to their best level of understanding (in line with legislative frameworks in England [24] and Scotland [25]). Where patients in England are assessed as lacking capacity to make a decision regarding their initial or continued involvement with the study, we will seek a personal or nominated consultee agreements [26]. In Scottish study sites where a patient is assessed not to have capacity, a legal representative will be sought and asked to consent in relation to the patient's participation in the research [27].

308 Approaching patients post-operatively

Where possible, the patient will be approached at a clinically suitable time approximately 48 hours (± 4 hours) following their operation. However, in order to facilitate patient recruitment and because successful collection of a sufficient number of pre-operative CSF samples is the priority for this study, sites are encouraged to screen and recruit patients from Monday-Friday. This is on the understanding that should a patient be consented on a Thursday/Friday, it may not be possible to complete the 48-hour follow-up due to insufficient Research Nurse cover during weekends. During the 48-hour follow-up point, we will aim to collect the post-operative blood sample and Mini-Mental State Examination - 2<sup>nd</sup> Edition, Short-Form version (MMSE~2: SV) data. As appropriate, the 

research nurse will remind the patient of the study, reassess capacity (as required) and complete pre-consented study related procedures. In English sites, for patients who previously provided informed consent on their own behalf but are as assessed as having since lost capacity at this followup point, we will seek a personal or nominated consultee agreements [24]. As part of the patient consent form for Trusts based in England, patients will be asked to provide contact details for someone who may be willing to act as a personal consultee in the event that the patient loses capacity. Patients will also be asked to sign an advanced statement of intent, stating that should they be assessed as having lost capacity post-operatively, they would still like to be involved in the study should a consultee be available. A more detailed overview of the recruitment process is shown in Figure 2: Recruitment overview.

**INSERT FIGURE 2: RECRUITMENT OVERVIEW AND PARTICIPANT FLOW** 

8 Data Collection

9 Day of Operation

The research nurse and/or anaesthetist at the time of the hip fracture operation will be responsible for collecting 18.5ml of whole blood (1 x 6.0ml of blood ethylenediaminetetraacetic acid (EDTA) tube, 2 x 5.0ml serum tube and 1 x 2.5ml PAXgene tube) and the collection of 2.0 – 6.0 ml of CSF (anaesthetist only).

Sites will be instructed to centrifuge CSF samples within one hour of sample collection at 2000G for 10 minutes. If CSF samples are not centrifuged within a maximum of 2 hours of collection, site teams will be informed to destroy the samples and alert the study management team accordingly. Blood serum samples will be centrifuged at 2000G for 15 minutes, within one hour of collection. If any blood serum samples are not centrifuged within 3 hours of collection, they must be rejected and destroyed; and the study management team notified accordingly. The EDTA and PAXgene samples will not require centrifugation and sites are instructed to leave these to rest at room temperature for 2 hours, following inversion.

Once processed and ready for storage, the CSF, EDTA and blood serum samples will be aliquotted into 0.5ml samples within 1.5ml capacity Cryotubes, and stored in a specific patient Cryobox. Both the Cryobox and all of the individual Cryotubes used for patient sample storage are labelled with the patient's unique study identifier number and colour coded to match the sample type being stored. PAXgene samples are also labelled accordingly but remain stored in their initial vacutainers, inside the corresponding patient's Cryobox. The Cryobox will then be stored in a -80° Celsius freezer at the local research site. All of the sample collection, processing and storage times for each patient will be recorded within the study's electronic database for monitoring purposes.

Once a site has successfully recruited and collected samples for 10 patients, the study management team will arrange for a courier to collect and deposit the samples at the Norwich Biorepository for long-term storage, until the final sample analysis is ready to be started. All sample transfers will be completed on a same day delivery basis, using dry ice to maintain sample cooling. Once at the Norwich Biorepository, samples will be monitored against the electronic database records and sample transfer log, for completeness and accuracy. Samples will then be deposited in a -80 Celsius freezer within the Norwich Biorepository. Any discrepancies will be followed up with the local research team and recorded in the electronic database accordingly.

Spinal anaesthesia will be performed according to local trust procedures. After placement of the needle to deliver the spinal anaesthetic, and prior to administration of the anaesthetic agent, a sample of between 2 – 6ml of CSF will be collected. Patients unable to provide a sufficient CSF sample will be withdrawn from the study and any prior samples collected destroyed according to Local Trust Policy.

363 During collection of the CSF, the patient will be monitored. Should the patient's discomfort become
364 too great, the anaesthetist will stop collecting the CSF. Headaches ('post-dural-puncture headache'
365 or 'PDPH') are a common side effect of spinal anaesthesia and typically occur within two to three
366 days following the procedure. After taking advice from anaesthetists, it was identified that the risk of

patients experiencing a PDPH may be slightly higher for patients taking part in this study because of the additional CSF withdrawn. The incidence of PDPH's will therefore be monitored as part of routine care using standard local procedures. Any PDPH observed by the clinical team will be assessed for severity and reported as an adverse event. The incidence rates of PDPH's will be monitored and review by the Data Monitoring and Ethics Committee (DMEC) and Study Steering Committee (SSC). However, the risk is expected to be negligible.

#### Post-op 48 hours (± 4 hours)

2 x 5.0ml blood (serum tube) will be collected from the patient. Every effort will be made to collect post-operative bloods within this time window, but this may not always be possible. Therefore, research nurses will collect the MMSE<sup>2</sup>: SV data and bloods at the next earliest opportunity but not beyond 60 hours post-op. The time point at which these samples and data are collected will be noted and fed into the analysis. Sites consistently collecting samples outside the 48 (± 4 hours) window will be reviewed by the Study Management Group (SMG) who will decide if they should be withdrawn. For patients recruited on a Thursday or Friday, it is accepted that this follow-up may not be possible due to insufficient Research Nurses across weekends.

#### Post-op 1-month (± 5 days)

The 1-month post-op period will provide clinical teams with an opportunity to contact the patient's General Practitioner (GP) and review their case notes to assess if the patient has a pre-existing documented diagnosis of dementia, as well as record some additional clinical measures and test results. If the patient has an eligible suitable informant, clinical teams will also use this time to complete IQCODE assessment if they have not already done so.

## INSERT TABLE 1: SAMPLE AND DATA COLLECTION SCHEDULE

389 Sample Size

We will recruit 200 patients with dementia and hip fracture; and 200 patients without dementia but who have experienced a hip fracture. This sample size is pragmatically based upon what would appear to be achievable in the time available and with consideration of likely statistical power. Without adjustment, a sample size of 200 subjects per group will provide statistical power of 90% to detect a mean between group mean differences of 0.33 standard deviations in any outcome variable using a two-sided significance level of 5%. Assuming confounding variables entered into a General Linear Model 'explain' no more than 25% of the total variation (i.e. the co-efficient of determination, R2, is less than 0.25), then this sample size should provide 90%. Power to detect an 'adjusted' mean difference of around 0.37 residual standard deviations [28]. In either case, this would be deemed a relatively small effect to be detected with high probability.

400 Data will be collected initially from two different groups:

401 Group 1: Pre-operative acute hip fracture patients with confusion;

402 Group 2: Pre-operative acute hip fracture patients without confusion.

In respect of Group 1 (those with confusion), the AMT (England) and 4AT (Scotland) score indicate that a patient may be living with dementia. However, this may not be confirmed until 1-month post-op when reviewing the patient's case notes, contacting their GP or reviewing their relevant Suitable Informant's IQCODE Scores. Based on prior research, we anticipate that up to 50% of patients who have an AMT score of 8 or less (England) or 4AT score of 1 or above (Scotland) will have dementia (diagnosed or undiagnosed/vectored) [23]. Therefore, up to 400 may need to be recruited to this group. Recruitment will be monitored and stopped for Group 1 as soon as we receive 200 patients with confirmed dementia required for the study.

We will also collect data from patients without confusion (Group 2), who are unlikely to beconfirmed with dementia at 1-month post-op. These patients will be included in the non-dementia

group. Again, recruitment will be monitored and stopped from this group once 200 non-dementia
patients have been included. The number required from this group will be dependent upon the nondementia confirmation rate for this group.

There will be a number of patients from Group 1 (Pre-operative acute hip fracture patients with confusion) for whom we cannot find evidence of dementia at 1-month post-op. The samples and data from this (confused, non-dementia) group will be deposited into a biobank at the Norwich Biorepository, for use in future research studies. In cases where patients were initially in Group 2 (Pre-operative acute hip fracture patients without confusion) but where evidence of dementia is available at 1 month post-op, we will reallocate these patients to the dementia patient group.

Comparable data will also be provided from a third group (Oslo Cohort) of 200 'stable' patients living with a confirmed dementia diagnosis, taken from existing memory clinic data (Norwegian Registry of Persons with Cognitive Symptoms (NorCog) (Reference: S-08143a and 2017/371). Samples for this group are already available, as lumbar puncture is part of the diagnostic workup of patients included in the Norcog registry (Reference: S-08143a). These samples were analysed in 2017 at Sahlgrenska for the following: Aβ38, Aβ40, Aβ42, 10xAb42/Ab40, YKL-40, IL-1β, IL-6, IL-8, TNF-α, G36-NG2. The respective regional committee responsible have already provided permission to compare these results with those gathered in the present study.

Thus, we shall assemble data from 3 groups (hip fracture and dementia, hip fracture and nondementia, stable and dementia), each with an expected 200 subjects. Please (see Figure 1: Study
diagram and group allocation of patients).

433 Analysis

All analyses will be conducted according to a detailed Statistical Analysis Plan (SAP), agreed by the
Study Management Group (SMG) prior to analysis. A summary of the main analyses are given below
however:

Primary hypothesis: We will address the primary hypothesis, that systemic inflammation arising
from hip fracture leads to an acute brain injury, by comparing the level of inflammatory and
neuronal injury CSF and blood markers between the three groups defined above. Accordingly, we
predict raised inflammatory and injury markers for the confirmed dementia-hip fracture group
compared to the medically stable dementia group (Oslo cohort) and compared to the non-dementia
hip fracture group.

Each of the markers will be compared across groups using a general linear model with the marker as the dependent variable (i.e. a separate model for each biomarker). The initial model will simply include group as an explanatory factor. A further model will then be constructed, including potential confounding variables, such as age, to provide an adjusted between group mean difference (comparing fracture patients with dementia to fracture patients without and fracture patients with dementia to stable dementia patients), together with 95% confidence intervals and significance test. In the event of the residuals for these models not appearing normally distributed, an appropriate transformation will be applied, such as a logarithmic transformation. We also predict that patients with dementia will have significantly worse cognitive and functional informant-based scores. A similar analysis will be conducted with cognitive and functional scores as the dependent variable. Secondary hypothesis: The secondary hypothesis is that the magnitude of the brain inflammatory response will predict the quantity of specific brain injury markers (phospho-tau, NfL, neurogranin, synaptotagmin, SNAP-25) measured in the CSF. The strength of inter-relationship between the inflammatory and injury markers outlined will be examined using correlation coefficients. These will also be adjusted for potential confounding factors using partial correlation coefficients. Analysis of the samples will take place at UEA, Trinity College Dublin and the University of Gothenburg. Should additional information become available during the course of the study, we will ensure that we use the most appropriate analysis available to answer the research questions.

CSF will be analysed for a number of inflammatory and neuronal injury markers. These
 include, but are not limited to: TNF-α, IL-1RA, IL-1β, IL-6, sTREM2, YKL-40, T-tau, P-tau, Aβ38, Aβ40,
 Aβ42, neurogranin, synaptotagmin and SNAP-25;

• Blood collected pre-operatively and at 48 hours ( $\pm$  4 hours) will be analysed for TNF- $\alpha$ , IL 1RA, IL-1 $\beta$ , IL-6, T-tau and NfL;

• Blood collected pre-operatively will also be genotyped for the APOE  $\epsilon 2/\epsilon 3/\epsilon 4$  polymorphism at UEA;

• PAXgene blood for later transcriptomic analysis looking for blood signatures that associate with, and may be predictive of, particular CSF and clinical outcomes in our patients.

## 470 Discussion

471 Despite significant investment, disease-modifying treatments for dementia are still absent and there 472 has been no significant treatment breakthrough for 15-20 years [29]. Inflammation is a vital part of 473 the immune system's response to injury and infection which may become harmful if exaggerated or 474 unresolved. There is now growing evidence that harmful inflammation in the brain is aetiological and 475 contributed to the pathophysiology of dementia [30].

Recent research highlights acute illnesses or injuries that cause inflammation throughout the body,
such as infection, trauma and surgery, can accelerate the speed of decline in dementia [31, 32]. For
example, an infection in a hospitalised older person with dementia is linked to a higher long-term
worsening of that person's symptoms. The underlying mechanisms linking inflammation, cognition
and dementia progression remain greatly under-researched, with almost no studies in humans. This
lack of research impacts on the search for new treatments targeting inflammation in dementia.

Thus this study will develop understandings of the role of inflammatory response in dementia and
support developing pharmaceutical interventions. Additionally it will inform ways to predict

485	finding new therapeutic targets.
486	Declarations
487	Ethics Approval and Consent to Participate
488	Due to the devolved legislative landscape in the United Kingdom, ethical approval was sought from
489	separate Research Ethics Committees in England and Scotland. Ethical approval was granted from
490	Newcastle & North Tyneside Research Ethics Committee (24.03.2017, reference number:
491	16/NE/0420) and Scotland Research Ethics Committee A (05.04.2017) reference number:
492	17/SS/0001) accordingly. Ethical approval permitted witnessed verbal consent. Ethical approval for
493	the Norwegian cohort of stable dementia patients has been granted via the Norwegian Registry of
494	Persons with Cognitive Symptoms [NorCog] (Reference: S-08143a and 2017/371). The trial is
495	registered with ISRCTN 43803769. Although an observational sample collection study by design,
496	where applicable the SPIRT guidelines have been used to guide the reporting of our study protocol.
497	Consent to Publish
498	Not applicable.
499	Availability of Data and Materials
500	Not applicable.
501	Competing Interests
502	The authors declare that they have no competing interests.
503	Funding
504	The impact of Acute SystematiC inflammation upon cerebRospinal fluId and blood BiomarkErs of
505	brain inflammation and injury in Dementia: A study in acute hip fracture patients: ASCRIBED Study is

deterioration in dementia. Exploration of new potential disease pathways remains essential for

fully funded by Alzheimer's Research UK (ARUK); grant number ARUK-PG2016B-12. Without the
financial support of ARUK, the current study would not have been possible. HZ is a Wallenberg
Academy Fellow and is additionally supported by grants from the European Research Council, the
Swedish Research Council and the UK Dementia Research Institute at UCL. ABK is supported by
grants from the Norwegian Health Association. The funders have had no role in the design of the
study, collection, analysis and interpretation of data, and in writing of the manuscript. Alzheimer's
Research UK provided independent peer review for this grant.

513 Authors' Contributions

CF, SH, JC, LS, AM, CC, HZ, LOW, ABK, RH and CB conceptualised and secured funding for the
research study; CF was the lead investigator for the funding application, while CC was the primary
author of the scientific hypothesis. NL, SH, CF, JC, LS, AM, MH, GH and AMM designed the study and
were involved in creating and refining the protocol. NL wrote the first draft of this publication with
contributions from SH (clinical operations) and LS (statistics). All authors contributed to revisions of
the manuscript, read and approved the final manuscript.

520 Acknowledgements

The authors are thankful for the ongoing support from principal investigators, site staff and the
Clinical Research Network in setting up and undertaking various aspects of the ASCRIBED Study. We
would also like to express our gratitude to those who reviewed the protocol including: the Study
Steering Committee and Norwich Clinical Trial Unit's Protocol Review Committee.

525 Study Status

526 Current Protocol Version 1.5 (11.01.2018). Recruitment for the study began on the 01<sup>st</sup> June 2017.
527 The current planned end of recruitment date is the 31<sup>st</sup> August 2019.

1	528	Abbre	eviations	
2 3 4	529	Abbrevi	ated Mental Test Score (AMTS), Alzheimer's Research UK (ARUK), Best Practice Tariff (BTP),	
5 6	530	cerebro	spinal fluid (CSF), Data Monitoring and Ethics Committee (DMEC),	
7 8 9	531	ethylen	ediaminetetraacetic acid (EDTA), General Practitioner (GP), Informant Questionnaire for	
10 11	532	Cognitiv	ve Decline in the Elderly (IQCODE), Mini-Mental State Examination - 2 <sup>nd</sup> Edition, Short-Form	
12 13	533	version	(MMSE~2: SV), National Health Service (NHS), National Hip Fracture Database (NHFD), neck	:
14 15 16	534	of femu	r (NOF), post-dural puncture headache (PDPH), Study Management Group (SMG), Study	
17 18	535	Steering	g Committee (SSC), United Kingdom (UK), Statistical Analysis Plan (SAP).	
19 20 21 22 23	536	Refer	ences	
24 24 25	537	1.	Krogseth, M., Watne, L.O., Juliebø, V., Skovlund, E., Engedal, K., Frihagen, F., & Wyller, T.B.	
26 27	538		Delirium is a risk factor for further cognitive decline in cognitively impaired hip fracture	
28 29 30	539		patients. Arch Gerontol Geriatr 2016, 64, 38-44.	
31 32	540	2.	Martinez-Reig, M., Ahmad, L., & Duque, G. The orthogeriatrics model of care: systematic	
33 34 35	541		review of predictors of institutionalization and mortality in post-hip fracture patients and	ł
36 37	542		evidence for interventions. J Am Med Dir Assoc 2012, 13(9), 770-777.	
38 39	543	3.	Tsuda, Y., Yasunaga, H., Horiguchi, H., Ogawa, S., Kawano, H., & Tanaka, S. Association	
40 41 42	544		between dementia and postoperative complications after hip fracture surgery in the	
43 44	545		elderly: analysis of 87,654 patients using a national administrative database. Arch Orthop	
45 46 47	546		Trauma Surg 2015, <b>135</b> (11), 1511-1517.	
48 49	547	4.	Heneka, M.T., Carson, M.J., El Khoury, J., Landreth, G.E., Brosseron, F., Feinstein, D.L., et al.	
50 51	548		Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015, 14(4), 388-405.	
52 53 54	549	5.	McGeer, P.L., Akiyama, H., Itagaki, S., & McGeer, E.G. Activation of the classical	
55 56	550		complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989, 107(1-3),	
57 58	551		341-346.	
59 60				
61 62				23
63 64				

1	552	6.	Neumann, H., & Daly, M.J. Variant TREM2 as risk factor for Alzheimer's disease. New
1 2 3	553		England Journal of Medicine 2013, <b>368</b> (2), 182-184.
4 5	554	7.	Hickman, S.E., Allison, E.K., & El Khoury, J. Microglial dysfunction and defective beta-
6 7 8	555		amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 2008, 28(33),
9 10	556		8354-8360.
11 12 13	557	8.	Heneka, M.T., Kummer, M.P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep,
13 14 15	558		A., Axt D., Remus, A., Tzeng, T.C., Gelpi, E., Halle, A., Korte, M., Latz, E., & Golenbock D.T.
16 17	559		NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice.
18 19 20	560		Nature 2013 <b>493</b> (7434), 674-678.
20 21 22	561	9.	Cunningham, C., Campion, S., Lunnon, K., Murray, C.L., Woods, J.F.C., Deacon, R.M.J.,
23 24	562		Rawlins, J.N.P., & Perry, V.H. Systemic Inflammation Induces Acute Behavioral and
25 26 27	563		Cognitive Changes and Accelerates Neurodegenerative Disease. Biological Psychiatry 2009,
28 29	564		<b>65</b> (4): 304-312.
30 31	565	10.	Brugg, B., Dubreuil, Y.L., Huber, G., Wollman, E.E., Delhaye-Bouchaud, N., & Mariani, J.
32 33 34	566		Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain.
35 36	567		Neurobiology 1995, <b>92</b> : 3032-3035.
37 38 39	568	11.	Murray, C., Sanderson, D.J., Barkus, C., Deacon, R.M.J., Rawlins, J.N.P., Bannerman, D.M.,
	569		Cunningham, C. Systemic inflammation induces acute working memory deficits in the
42 43	570		primed brain: relevance for delirium. Neurobiology of Aging 2012, 33(3): 603-616.
44 45 46	571	12.	Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry,
47 48	572		V.H. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009,
49 50	573		<b>73</b> (10): 768-774.
51 52 53	574	13.	Holmes, C., Cunningham, C., Zotova, E., Culliford, D., & Perry, V. Proinflammatory cytokines,
54 55	575		sickness behavior, and Alzheimer disease. Neurology 2011, 77: 212-218.
56 57			
58 59 60			
61 62			24
63 64			24
65			

1	576	14.	Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry,
1 2 3	577		V. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009
4 5	578		<b>73</b> : 768-774.
6 7 8	579	15.	Jorm, A. F. A Short-Form of the Informant Questionnaire on Cognitive Decline in the Elderly
9 10	580		(IQCODE) - Development and Cross-Validation. Psychological Medicine 1994, 24(1), 145-
11 12	581		153.
13 14 15	582	16.	National Hip Fracture Database: <u>https://www.nhfd.co.uk</u>
16 17	583	17.	Hodkinson, H. M. Evaluation of a mental test score for assessment of mental impairment in
18 19 20	584		<b>the elderly</b> . <i>Age Ageing</i> 1972, <b>4</b> : 233-8.
21 22	585	18.	Bellelli, G., Morandi, A., Davis, D. H., Mazzola, P., Turco, R., Gentile, S., Ryan, T., Cash, H.,
23 24	586		Guerini, F., Torpilliesi, T., Del Santo, F., Trabucchi, M., Annoni, G., MacLullich, A. M.
25 26 27	587		Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234
28 29	588		hospitalised older people. Age Ageing 2014, 43: 496-502.
30 31	589	19.	Swain, D. G. & Nightingale, P. G. Evaluation of a shortened version of the Abbreviated
32 33 34	590		Mental Test in a series of elderly patients. Clin Rehabil 1997, 11(3): 243-248.
35 36	591	20.	Schofield, I., Stott, D.J., Tolson, D., McFadyen, J., Monaghan, J., & Nelson, D. Screening for
37 38 20	592		cognitive impairment in older people attending accident and emergency using the 4-item
39 40 41	593		Abbreviated Mental Test. Eur J Emerg Med 2010, 17(6):340-342.
42 43	594	21.	Jorm, A F. The Informant Questionnaire on cognitive decline in the elderly (IQCODE): a
44 45 46	595		review. International Psychogeriatrics 2004, 16(3) 275-93.
47 48	596	22.	Harrison, J. K., Fearon, P., Noel-Storr, A.H., McShane, R., & Stott, D.J., Quinn TJ. Informant
49 50	597		Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia
51 52 53	598		within a secondary care setting. Cochrane Database of Systematic Reviews (CDSR) 2015,
54 55	599		<b>10</b> (3).
56 57	600	23.	Hammond, S.P, Cross, J.L., Shepstone L., Backhouse, T., Henderson, C., Poland, F., Sims, E.,
58 59 60	601		MacLullich, A., Penhale, B., Howard, R., Lambert, N., Varley, A., Smith, T.O., Sahota, O.,
61 62			25
63 64			23

	602
1 2 3	603
4 5	604
6 7 8	605
9 10	606
11 12 13	607
14 15	608
16 17 18	609
18 19 20	610
21 22	611
23 24 25	612
26 27	613
28 29	614
30 31 32	615
33 34	616
35 36	617
37 38 39	618
40 41	619
42 43 44	620
44 45 46	621
47 48	622
49 50 51	623
52 53	624
54 55	625
56 57 58	626
59	
60 61	
62	
63	

Donell, S., Patel, M., Ballard, C., Young, J., Knapp, M., Jackson, S., Waring, J., Leavey, N., Howard, G., & Fox, C. PERFECTED enhanced recovery (PERFECT-ER) care versus standard acute care for patients admitted to acute settings with hip fracture identified as experiencing confusion: study protocol for a feasibility cluster randomized controlled trial.

Trials 2017, 18: 583.

- 24. Act MC: Code of practice. Department for Constitutional Affairs London: TSO 2005.
- 25. Parliament S: Adults with Incapacity (Scotland) Act 2000. 2000.
- 26. Harwood, R.H., Goldberg, S.E., Whittamore, K.H., Russell, C., Gladman, J.R., Jones, R.G.,
  - Porock, D., Lewis, S.A., Bradshaw, L.E., & Elliot, R.A. Evaluation of a Medical and Mental
- Health Unit compared with standard care for older people whose emergency admission to
  - an acute general hospital is complicated by concurrent'confusion': a controlled clinical
- trial. Acronym: TEAM: Trial of an Elderly Acute care Medical and mental health unit. Trials 2011, **12:**1.
  - 27. Young, J., Cheater, F., Collinson, M., Fletcher, M., Forster, A., Godfrey, M., Green, J., Anwar,

# S., Hartley, S., & Hulme, C. Prevention of delirium (POD) for older people in hospital: study protocol for a randomised controlled feasibility trial. *Trials* 2015, **16**:1.

- 28. Lipsitz, S.R., & Parzen, M. Sample size calculations for non-randomised studies. Statistician 1995, 44(1) 81-90.
- 29. Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., Fratiglioni, L., Frisoni, G.B., Gauthier, S., Georges,
- J., Graff, C., Iqbal, K., Jessen, F., Johansson, G., Jönsson, L., Kivipelto, M., Knapp, M.,
- Mangialasche, F., Melis, R., Nordberg, A., Rikkert, M. O., Qiu, C., Thomas, P.S., Scheltens, P.,
- Schneider, L.S., Sperling, R., Tjernberg, L.O., Waldemar, G., Wimo, A., & Zetterberg, H.

Defeating Alzheimer's disease and other dementias: a priority for European science and

- society. The Lancet Neurology Commission 2016, 15(5): 455-532.

1	627	30. Perry, V.H. The influence of systemic inflammation on inflammation in the brain:
1 2 3	628	implications for chronic neurodegenerative disease. Brain, Behavior, and Immunity 2004,
4 5	629	<b>18</b> (5): 407-413.
6 7 8	630	31. Tsai, H.H., Yen, R.F., Lin, C.L., & Kao, C.H. Increased risk of dementia in patients hospitalized
9 10	631	with acute kidney injury: A nationwide population-based cohort study. PLoS ONE 2017,
11 12 13	632	<b>12</b> (2): Article IDe0171671, 2017.
14 15	633	32. Rajaneesh, G., & Sen, N. Traumatic brain injury: a risk factor for neurodegenerative
16 17	634	diseases. Reviews in the Neurosciences 2016, 27(1): 93-100.
18 19 20	635	
21 22	636	
23 24 25	637	
25 26 27	638	
28 29	639	
30 31 32 33	640	
34 35	641	Figure Titles/Legends
36 37 38	642	Figure 1: Study Diagram and Group Allocation of Patients
39 40 41	643	Figure 2: Recruitment Overview and Participant Flow
42 43	644	Table 1: Sample and Data Collection Schedule
44 45 46 47 48 49 50 51 52 53 55 57 58 50 60 1 62	645 646 647 648 649	<ul> <li><sup>1</sup> Taken if patient's capacity status has changed from pre-operative time period (Eng. only);</li> <li><sup>1</sup> Should the time window be unworkable, research nurses will collect MMSE~2: SV data and bloods at the next earliest opportunity but not beyond 60 hours post-op;</li> <li><sup>1</sup> Can be gained at any point before the 1-month (± 5 days) time period elapses.</li> </ul>
63 64		۷۲

	Admission/Pre-Op Period	Day of Operation	Post-Op Period		
TIMEPOINT		Day 0	48 (± 4 hours) post-op	Time 1 (1 month ± 5 days)	
Consent/ Agreement	Х		X1		
AMT and/or 4AT	Х		X <sup>2</sup>		
Collection of blood EDTA sample (6 ml)		Х			
Collection of blood serum clotted sample (10 ml)		х	X <sup>2</sup>		
Collection of Cerebrospinal fluid (CSF) sample (≥ 2.0ml)		х			
MMSE~2: SV			X <sup>2</sup>		
IQCODE (To be completed by the suitable informant)			X <sup>3</sup>		
Evidence of dementia from patient's medical/GP records				X³	
Medication information				X <sup>3</sup>	
Collection of blood PAXgene RNA sample (2.5ml)		Х			

## Table 1: Sample and Data Collection Schedule


<sup>&</sup>lt;sup>1</sup> Taken if patient's capacity status has changed from pre-operative time period (Eng. only);

<sup>&</sup>lt;sup>2</sup> Should the time window be unworkable, research nurses will collect MMSE~2: SV data and bloods at the next earliest opportunity but not beyond 60 hours post-op;


 $<sup>^{3}</sup>$  Can be gained at any point before the 1-month (± 5 days) time period elapses.

<u>±</u>

## Figure 1: Study diagram and allocation of patients



<u>±</u>



## Figure 2: Recruitment overview and participant flow

\*If an eligible suitable informant is available: Consent Taken and IQCODE completed – This can be completed anytime from consent/consultee advice being taken up to 1-month post-operatively.